Evaluation of pneumococcal meningitis clusters in Burkina Faso and implications for potential reactive vaccination
| العنوان: | Evaluation of pneumococcal meningitis clusters in Burkina Faso and implications for potential reactive vaccination |
|---|---|
| المؤلفون: | Brice Bicaba, Absatou Ky Ba, Malika Congo-Ouédraogo, Soumeya Ouangraoua, Isaïe Medah, Guetawendé Sawadogo, Srinivasan Velusamy, Heidi M Soeters, Abdoul-Salam Ouédraogo, Chris A. Van Beneden, Cynthia G. Whitney, Issaka Yaméogo, Lesley McGee, Flavien Aké, Rasmata Ouédraogo-Traoré, Dinanibè Kambiré, Lassana Sangaré |
| المصدر: | Vaccine |
| بيانات النشر: | Elsevier BV, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Serotype, Pediatrics, medicine.medical_specialty, 030231 tropical medicine, medicine.disease_cause, Pneumococcal Infections, Article, Pneumococcal conjugate vaccine, Pneumococcal Vaccines, 03 medical and health sciences, 0302 clinical medicine, Burkina Faso, Streptococcus pneumoniae, medicine, Humans, 030212 general & internal medicine, Retrospective Studies, Vaccines, Conjugate, Surveillance, General Veterinary, General Immunology and Microbiology, Meningitis, Pneumococcal, business.industry, Incidence, Incidence (epidemiology), Vaccination, Outbreaks, Public Health, Environmental and Occupational Health, Infant, Outbreak, Pneumococcal meningitis, medicine.disease, Latex fixation test, Infectious Diseases, Molecular Medicine, business, Meningitis, medicine.drug |
| الوصف: | Highlights • From 2011 to 2017, Burkina Faso had 20 pneumococcal meningitis clusters of ≥ 5 cases per district/week. • Clusters had a maximum weekly incidence of 7 cases and a maximum duration of 4 weeks. • Most clusters occurred prior to 13-valent pneumococcal conjugate vaccine introduction. • Clusters were caused by a mixture of serotypes, with serotype 1 being most common. • Due to the limited cluster size and duration, there were no clear indications for reactive vaccination. Background To better understand how to prevent and respond to pneumococcal meningitis outbreaks in the meningitis belt, we retrospectively examined Burkina Faso’s case-based meningitis surveillance data for pneumococcal meningitis clusters and assessed potential usefulness of response strategies. Methods Demographic and clinical information, and cerebrospinal fluid laboratory results for meningitis cases were collected through nationwide surveillance. Pneumococcal cases were confirmed by culture, polymerase chain reaction (PCR), or latex agglutination; strains were serotyped using PCR. We reviewed data from 2011 to 2017 to identify and describe clusters of ≥ 5 confirmed pneumococcal meningitis cases per week in a single district. We assessed whether identified clusters met the 2016 WHO provisional pneumococcal meningitis outbreak definition: a district with a weekly incidence of >5 suspected meningitis cases/100,000 persons, >60% of confirmed meningitis cases caused by Streptococcus pneumoniae, and >10 confirmed pneumococcal meningitis cases. Results Twenty pneumococcal meningitis clusters were identified, with a maximum weekly incidence of 7 cases and a maximum duration of 4 weeks. Most identified clusters (15/20; 75%) occurred before nationwide introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013. Most cases were due to serotype 1 (74%), 10% were due to PCV13 serotypes besides serotype 1, and 8 clusters had >1 serotype. While 6 identified clusters had a weekly incidence of >5 suspected cases/100,000 and all 20 clusters had >60% of confirmed meningitis cases due to S. pneumoniae, no cluster had >10 confirmed pneumococcal meningitis cases in a single week. Conclusions Following PCV13 introduction, pneumococcal meningitis clusters were rarely detected, and none met the WHO provisional pneumococcal outbreak definition. Due to the limited cluster size and duration, there were no clear instances where reactive vaccination could have been useful. More data are needed to inform potential response strategies. |
| تدمد: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2020.06.002 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c55ea76691880376eb28ee81330d49 https://doi.org/10.1016/j.vaccine.2020.06.002 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....01c55ea76691880376eb28ee81330d49 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 0264410X |
|---|---|
| DOI: | 10.1016/j.vaccine.2020.06.002 |